Insights & Discussion
Green tea extract has shown promising results in reducing uterine fibroid volume, fibroid-related symptoms, and improving quality of life in women with symptomatic uterine fibroids.
The research examined the effect of green tea extract (epigallocatechin gallate, EGCG) on uterine fibroid (UF) management. In this randomized, double-blinded, placebo-controlled study, 39 women aged 18-50 presenting with symptomatic UF were enlisted. Participants were confirmed as eligible through transvaginal ultrasonography that showed at least one 2cm³ or larger fibroid lesion. They were split into two groups: the focus group took a daily oral intake of 800 mg of green tea extract, while the control group followed the same regimen with 800 mg of brown rice (placebo). The experiment period ran for four months. At the end, UF volume changes were also measured through transvaginal ultrasonography for comparison.
The outcome revealed divergent changes in UF volume and health-related quality of life (HRQL) among participants. In the placebo group, an increase in fibroid volume was noticed. Contrarily, significant reductions in fibroid volume and symptom severity were recorded in women who took green tea extract. This group also witnessed an improvement in HRQL contrasted to the control group. Additionally, anemia improved in the EGCG treatment group, with no adverse effects or endometrial anomalies reported in either group.
Discover Related Insights
Epigallocatechin gallate (EGCG), a green tea component, showed potential in treating uterine fibroids and associated infertility without causing liver toxicity or folate deficiency.
2023 Nutrients Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women Siblini H, Al-Hendy A, Segars J, González F, Taylor HS, Singh B, et al.
Cohort Study EGCG Green Tea Uterine Fibroids
The study involved the pre-testing of a green tea substance known as Epigallocatechin gallate (EGCG) on a cohort of premenopausal women, aged 18 to 40, with and without uterine fibroids, in order to evaluate its safety. The subjects were randomized into three groups, each receiving different treatments. One group took just a daily dose of 800 mg of EGCG, one group combined this EGCG dose with 100 mg of Clomiphene citrate for five days, and the third group combined it with 5 mg of Letrozole for the same period.
The results showed that none of the subjects displayed signs of drug-induced liver injury, and all had normal serum folate levels. Hence, the findings suggest that the daily intake of 800mg of EGCG, whether consumed alone or in combination with Clomiphene citrate or Letrozole for five days, is well-tolerated and not related to any liver toxicity or folate deficiency in women of reproductive age.
Combining Crila with green tea extract (EGCG) has been found to synergistically hinder the growth of human uterine fibroid cells.
2023 F&S Science The combination of natural compounds Crila and epigallocatechin gallate (EGCG) showed enhanced antiproliferative effects on human uterine fibroid cells compared to single treatments. Bai T, Ali M, Somers B, Yang Q, McKinney S, Al-Hendy A
Network Pharmacology EGCG Uterine Fibroids
In the methodological process, human uterine leiomyoma (HuLM) cells were treated with varying concentrations of Crila, either alone or combined with epigallocatechin gallate (EGCG), employing various tests. Prominently, assays were performed to examine cell proliferation, with additional analyses conducted to measure protein and gene expressions of proliferation markers.
The interaction of Crila and EGCG resulted in a notable reduction in HuLM cell viability, showing an increased inhibitory effect over singular treatments. This decrease in cell proliferation is attributed to a synergistic efficacy derived from using Crila and EGCG in combination. It was notably characterised by the reduced presence of the proliferation marker, proliferating cell nuclear antigen, both at the messenger RNA and protein levels. It was observed that the process does not induce cell apoptosis, implying that the cell viability reduction is primarily due to decreased cell proliferation.
Green tea extract, specifically epigallocatechin gallate, can inhibit tumor growth and enhance the quality of life in women suffering from uterine fibroids.
2022 International Journal of Health Sciences The use of green tea in the treatment of symptomatic uterine fibroids Badawy A, Shady NW, Maklad SMA, Ait-Allah AS
Randomised Controlled Trial EGCG Green Tea Uterine Fibroids
A total of 75 reproductive-age women with symptomatic uterine fibroids were included in a prospective, randomized control trial. The selection of participants for either group, those receiving 900 mg of green tea extract or those receiving symptomatic treatment, was done via a random, blind method using sealed envelopes. This trial took place over a span of 4 months and the overall study lasted around 3 years.
The results of the study showcased the potency of green tea extract, particularly EGCG, with special regard to its anticancer properties. These manifested as anti-inflammatory, antiproliferative, and antioxidant effects. It was found that the administration of EGCG managed to influence tumor growth pathways, indicating its efficacy in dealing with uterine fibroids. Moreover, another significant progression was observed in the quality of life for the women partaking in this trial. It was confirmed that the use of EGCG could bring about an overall improvement in the living conditions of these women, contributing towards a better, healthier life amidst the struggle with their condition.